The new Alzheimer’s Assessment is a significant advancement in the early detection of Alzheimer’s disease. By leveraging the p-Tau217 biomarker, this simple blood test provides highly accurate results that can identify Alzheimer’s disease years before clinical symptoms appear, allowing for early intervention and management of the disease. The test offers a less invasive alternative to traditional cerebrospinal fluid and imaging tests, making it an accessible and convenient tool in the fight against Alzheimer’s.

Genova Diagnostics has long been at the forefront of diagnostic innovation, providing healthcare practitioners and individuals with the tools they need to make informed decisions about their health. The collaboration with Neurocode exemplifies Genova’s commitment to advancing medical research and expanding its portfolio of diagnostic solutions.